Forest Laboratories (FRX) 99.00 $FRX
Global Fibromyalgia Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phv6sx/fibromyalgia) has announced the addition of the "Fibromyalgia Global Clinical Trials Review, H1, 2014" report to their offering. Fibromyalgia Global Clinical Trials Review, H1, 2014" provides data on the Fibromyalgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fibromyalgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fibromyalgia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Forest Laboratories, Inc. - Eli Lilly and Company - Tonix Pharmaceuticals Holding Corp. - Jazz Pharmaceuticals plc - UCB S.A. - Laboratoires Pierre Fabre SA - Rose Pharmed Biotechnology Co. - GlaxoSmithKline plc - Boehringer Ingelheim GmbH - The University of Granada - National Center for Complementary and Alternative Medicine - National Institute of Arthritis and Musculoskeletal and Skin Diseases - Federal University of Sao Paulo - University of Michigan - Stanford University - Duke University - The Tel Aviv Sourasky Medical Center - University of Gothenburg - U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/ph...bromyalgia
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Why Salix Pharmaceuticals' Good Data Wasn't Great
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jul 02, 8:30AM CDT
Investors in Salix Pharmaceuticals might have had some upset stomachs in the days leading up to today's announcement of positive results from the TARGET-3 study of Xifaxan in IBS-D. Although a medical journal review from mid-2012...
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition
PR Newswire - Wed Jul 02, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest"
regarding their preference as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest.
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
2 Obamacare Supreme Court Ruling "Losers" That Didn't Really Lose
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 01, 12:47PM CDT
Put Obamacare in the losers' bracket this week. On Monday, the U.S. Supreme Court announced a 5-4 decision that prevents the federal government from requiring under the Affordable Care Act that some companies to offer health insurance coverage for...
Actavis closes $28B Forest deal, names new CEO
By The Associated Press - AP - Tue Jul 01, 9:23AM CDT
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition
PR Newswire - Tue Jul 01, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders. The Company also announced that Paul M. Bisaro, formerly the Chairman and Chief Executive Officer of Actavis, has been named to the newly created position of Executive Chairman of the Board of Actavis plc. The changes to the Actavis Board follow the completion of Actavis' acquisition of Forest Laboratories, Inc. in a cash and stock transaction currently valued at approximately $28 billion, and are effective until Actavis' next annual meeting of shareholders in May 2015.
Actavis Completes Forest Laboratories Acquisition
PR Newswire - Tue Jul 01, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity transaction currently valued at approximately $28 billion. The combination creates one of the world's fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015.
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Business Wire - Mon Jun 30, 4:15PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014.
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Business Wire - Mon Jun 30, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1st, 2014.
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
Global Fibromyalgia Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phv6sx/fibromyalgia) has announced the addition of the "Fibromyalgia Global Clinical Trials Review, H1, 2014" report to their offering. Fibromyalgia Global Clinical Trials Review, H1, 2014" provides data on the Fibromyalgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fibromyalgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fibromyalgia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Forest Laboratories, Inc. - Eli Lilly and Company - Tonix Pharmaceuticals Holding Corp. - Jazz Pharmaceuticals plc - UCB S.A. - Laboratoires Pierre Fabre SA - Rose Pharmed Biotechnology Co. - GlaxoSmithKline plc - Boehringer Ingelheim GmbH - The University of Granada - National Center for Complementary and Alternative Medicine - National Institute of Arthritis and Musculoskeletal and Skin Diseases - Federal University of Sao Paulo - University of Michigan - Stanford University - Duke University - The Tel Aviv Sourasky Medical Center - University of Gothenburg - U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/ph...bromyalgia
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Why Salix Pharmaceuticals' Good Data Wasn't Great
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jul 02, 8:30AM CDT
Investors in Salix Pharmaceuticals might have had some upset stomachs in the days leading up to today's announcement of positive results from the TARGET-3 study of Xifaxan in IBS-D. Although a medical journal review from mid-2012...
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition
PR Newswire - Wed Jul 02, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest"
regarding their preference as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
2 Obamacare Supreme Court Ruling "Losers" That Didn't Really Lose
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 01, 12:47PM CDT
Put Obamacare in the losers' bracket this week. On Monday, the U.S. Supreme Court announced a 5-4 decision that prevents the federal government from requiring under the Affordable Care Act that some companies to offer health insurance coverage for...
Actavis closes $28B Forest deal, names new CEO
By The Associated Press - AP - Tue Jul 01, 9:23AM CDT
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition
PR Newswire - Tue Jul 01, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders. The Company also announced that Paul M. Bisaro, formerly the Chairman and Chief Executive Officer of Actavis, has been named to the newly created position of Executive Chairman of the Board of Actavis plc. The changes to the Actavis Board follow the completion of Actavis' acquisition of Forest Laboratories, Inc. in a cash and stock transaction currently valued at approximately $28 billion, and are effective until Actavis' next annual meeting of shareholders in May 2015.
Actavis Completes Forest Laboratories Acquisition
PR Newswire - Tue Jul 01, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity transaction currently valued at approximately $28 billion. The combination creates one of the world's fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015.
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Business Wire - Mon Jun 30, 4:15PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014.
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Business Wire - Mon Jun 30, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1st, 2014.
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
